The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACCELERATE DIAGNOSTICS INC NOTE 5.000%12/1 00430HAC6   12,342,999 24,685,998 PRN   SOLE   24,685,998 0 0
BANDWIDTH INC NOTE 0.500% 4/0 05988JAD5   32,167,800 40,250,000 PRN   SOLE   40,250,000 0 0
BLUE OWL CAP CORP III COM SHS 69122G102   40,280,338 2,793,366 SH   SOLE   2,793,366 0 0
EQUITY COMWLTH COM SH BEN INT 294628102   16,903,500 9,550,000 SH   SOLE   9,550,000 0 0
ESPERION THERAPEUTICS INC NE COM 29664W105   6,600,000 3,000,000 SH   SOLE   3,000,000 0 0
IRONWOOD PHARMACEUTICALS INC NOTE 1.500% 6/1 46333XAH1   13,035,400 14,000,000 PRN   SOLE   14,000,000 0 0
ON24 INC COM 68339B104   27,392,054 4,240,256 SH   SOLE   4,240,256 0 0
REVANCE THERAPEUTICS INC NOTE 1.750% 2/1 761330AB5   24,030,000 25,000,000 PRN   SOLE   25,000,000 0 0
SUMMIT HOTEL PPTYS NOTE 1.500% 2/1 866082AA8   21,965,949 22,664,000 PRN   SOLE   22,664,000 0 0
TRAVERE THERAPEUTICS INC NOTE 2.500% 9/1 761299AB2   12,829,700 13,000,000 PRN   SOLE   13,000,000 0 0